Neuronetics Q1 2026 revenue rises 8% to $34.5M with improved cash flow and expanded therapy access

Neuronetics reported an 8% revenue increase to $34.5 million in Q1 2026, driven by a 15% rise in U.S. clinic revenue. The company shipped 34 NeuroStar systems, a 10% increase year-over-year, and reduced net cash used in operations by $7.6 million compared to Q1 2025. Operational improvements include expanded insurance coverage allowing nurse practitioners to administer NeuroStar therapy, broadening patient access. Neuronetics expects mid-single-digit revenue growth in Q2 2026 and projects full-year revenue between $160 million and $166 million.